Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Autor: Kommoss S; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Winterhoff B; Division of Gynecologic Surgery, Mayo Clinic, Minnesota.; Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minnesota., Oberg AL; Department of Health Sciences Research, Mayo Clinic, Minnesota., Konecny GE; Division of Medical Oncology, UCLA, California., Wang C; Department of Health Sciences Research, Mayo Clinic, Minnesota., Riska SM; Department of Health Sciences Research, Mayo Clinic, Minnesota., Fan JB; AnchorDx Corporation, Guangzhou, China.; Illumina Inc., San Diego, California., Maurer MJ; Department of Health Sciences Research, Mayo Clinic, Minnesota., April C; Illumina Inc., San Diego, California., Shridhar V; Department of Laboratory Medicine, Mayo Clinic, Minnesota., Kommoss F; Institute of Pathology, Mannheim, Germany., du Bois A; Kliniken Essen Mitte (KEM), Deptartment of Gynecology and GynecologicOncology, Essen, Germany., Hilpert F; Department of Gynecology and Obstetrics, Schleswig-Holstein University, Kiel, Germany., Mahner S; Department of Obstetrics and Gynecology, Ludwig Maximillian University Munich, Germany., Baumann K; Department of Gynecology and Gynecologic Oncology, Philipps University Marburg, Germany., Schroeder W; Gynaecologicum Bremen, Bremen, Germany., Burges A; Klinikum der Universitaet Muenchen, Campus Grosshadern, Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe, Munich, Germany., Canzler U; Department of Gynecology and Obstetrics, Technical University Dresden, Dresden, Germany., Chien J; Department of Cancer Biology, University of Kansas Cancer Center, Kansas City, Kansas., Embleton AC; Medical Research Council Clinical Trials Unit at University College London, UK., Parmar M; Medical Research Council Clinical Trials Unit at University College London, UK., Kaplan R; Medical Research Council Clinical Trials Unit at University College London, UK., Perren T; Leeds Institute of Cancer Medicine and Pathology, University of Leeds, UK., Hartmann LC; Division of Medical Oncology, Mayo Clinic, Minnesota., Goode EL; Department of Health Sciences Research, Mayo Clinic, Minnesota., Dowdy SC; Division of Gynecologic Surgery, Mayo Clinic, Minnesota. dowdy.sean@mayo.edu., Pfisterer J; Gynecologic Oncology Center, Kiel, Germany.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Jul 15; Vol. 23 (14), pp. 3794-3801. Date of Electronic Publication: 2017 Feb 03.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

Autor: Ledermann JA; Cancer Research UK and UCL Cancer Trials Centre, University College London and UCL Hospitals, London, UK. Electronic address: j.ledermann@ucl.ac.uk., Embleton AC; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Raja F; University College London Hospitals, London, UK., Perren TJ; St James's Institute of Oncology and Leeds Institute of Cancer Medicine and Pathology, Leeds, UK., Jayson GC; Christie Hospital and University of Manchester, Manchester, UK., Rustin GJS; Mount Vernon Cancer Centre, Northwood, UK., Kaye SB; Royal Marsden Hospital, London, UK., Hirte H; Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada., Eisenhauer E; Canadian Cancer Trials Group (CCTG) and Queen's University, Kingston, ON, Canada., Vaughan M; Christchurch Hospital, Christchurch, New Zealand., Friedlander M; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia., González-Martín A; Spanish Group for Investigation in Ovarian Cancer (GEICO) and MD Anderson Cancer Center Madrid, Madrid, Spain., Stark D; University of Leeds, Leeds, UK., Clark E; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Farrelly L; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Swart AM; University of East Anglia, Norwich, UK., Cook A; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Kaplan RS; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK., Parmar MKB; Medical Research Council Clinical Trials Unit at UCL, University College London, London, UK.

Publikováno v: Lancet (London, England) [Lancet] 2016 Mar 12; Vol. 387 (10023), pp. 1066-1074.